AgomAb Initiates Phase 2b Trial for Crohn's Disease Drug Ontunisertib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: NASDAQ.COM
- Trial Design Announcement: AgomAb Therapeutics has unveiled the Phase 2b NOV-ERA trial design for Ontunisertib, an oral small molecule targeting Fibrostenosing Crohn's Disease, aligning with FDA guidelines, indicating the company's strategic positioning in the treatment landscape.
- Patient Recruitment Plan: The company plans to enroll up to 320 patients globally, with participants required to meet specific endoscopic assessment criteria, demonstrating AgomAb's commitment to rigorous clinical trials and addressing unmet patient needs in a market lacking approved therapies.
- Trial Timeline: The trial will consist of a 6-week screening period, a 52-week treatment phase, and a 2-week follow-up, with the primary efficacy endpoint set for Week 24 regarding endoscopic passability, reflecting the company's focus on clinical outcomes and potential market competitiveness.
- Market Outlook Analysis: The global Crohn's disease therapeutics market is projected to reach $13.20 billion in 2023, growing at a CAGR of 2.7% from 2024 to 2030, positioning AgomAb's drug development efforts to capitalize on this rapidly expanding market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGMB
Wall Street analysts forecast AGMB stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.870
Low
Averages
High
Current: 11.870
Low
Averages
High
About AGMB
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Universe Pharma Acquires Patent Portfolio, Shares Surge
- Strategic Acquisition: Universe Pharmaceuticals Inc. (UPC) announced a $10.75 million acquisition of 100% of Best Praise International Limited, securing five Chinese patents covering elderly healthcare and cognitive health, with the deal expected to close in Q3 2026, significantly enhancing its competitive edge in the pharmaceutical market.
- Stock Surge: Following the acquisition announcement, UPC's shares soared over 300% to close at $12.18 on Monday, reflecting strong market confidence in its future growth potential and solidifying its position in the Chinese pharmaceutical industry.
- PIPE Financing: Decoy Therapeutics Inc. (DCOY) announced a PIPE financing of up to $21 million, leading to a 70% stock price increase, which includes $3.5 million in upfront proceeds, indicating strong market recognition of its funding capabilities and expected support for future R&D.
- Exploring Business Sale: QuidelOrtho Corp. (QDEL) shares rose over 30% as it explores the sale of its point-of-care testing business for approximately $1.5 billion, attracting interest from several private equity firms, which could provide significant capital inflow to support its strategic transformation.
See More
AgomAb Initiates Phase 2b Trial for Crohn's Disease Drug Ontunisertib
- Trial Design Announcement: AgomAb Therapeutics has unveiled the Phase 2b NOV-ERA trial design for Ontunisertib, an oral small molecule targeting Fibrostenosing Crohn's Disease, aligning with FDA guidelines, indicating the company's strategic positioning in the treatment landscape.
- Patient Recruitment Plan: The company plans to enroll up to 320 patients globally, with participants required to meet specific endoscopic assessment criteria, demonstrating AgomAb's commitment to rigorous clinical trials and addressing unmet patient needs in a market lacking approved therapies.
- Trial Timeline: The trial will consist of a 6-week screening period, a 52-week treatment phase, and a 2-week follow-up, with the primary efficacy endpoint set for Week 24 regarding endoscopic passability, reflecting the company's focus on clinical outcomes and potential market competitiveness.
- Market Outlook Analysis: The global Crohn's disease therapeutics market is projected to reach $13.20 billion in 2023, growing at a CAGR of 2.7% from 2024 to 2030, positioning AgomAb's drug development efforts to capitalize on this rapidly expanding market.
See More
AgomAb Therapeutics Reports Increased Losses for 2025
- Increased Annual Loss: AgomAb Therapeutics NV reported a net loss of €62.5 million for the full year 2025, up from €46.3 million in 2024, indicating significant financial strain and challenges in profitability management.
- Loss Per Share: The basic and diluted loss per share was €143.22, highlighting ongoing operational challenges that could impact investor confidence and future fundraising efforts.
- R&D Spending Growth: Research and development expenses rose to €48.9 million in 2025 from €39.3 million in 2024, reflecting the company's commitment to drug development despite not achieving profitability in the short term.
- Cash Position: As of December 31, 2025, AgomAb held €116.5 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, may be insufficient to sustain operations amid ongoing losses.
See More
Agomab Reports 2025 Financial Results and Future Milestones
- Expanded Financial Loss: Agomab Therapeutics reported a net loss of €62.55 million for the fiscal year 2025, up from €46.27 million the previous year, indicating increased R&D expenditures that may pressure short-term stock performance.
- Strong Cash Reserves: As of December 31, 2025, the company held €116.5 million in cash and cash investments, with gross proceeds of $208 million from its IPO expected to extend its cash runway into the first half of 2029, ensuring operational stability for the coming years.
- Clinical Trial Advancements: Agomab is set to initiate a Phase 2b study for Fibrostenosing Crohn's Disease and a Phase 2 study for Idiopathic Pulmonary Fibrosis in the second half of 2026, demonstrating the company's commitment to advancing its key investigational candidates.
- Stock Price Fluctuations: Since February 2026, AGMB shares have traded between $9 and $17.45, closing at $10.70, reflecting a cautiously optimistic market sentiment regarding the company's upcoming clinical results.
See More
Agomab's IPO Boosts Cash Runway into 2029
- Successful IPO Financing: Agomab completed its IPO in February 2026, raising approximately $208 million in gross proceeds, which is expected to extend the company's cash reserves into the first half of 2029, ensuring funding for its R&D and operational needs.
- Clinical Trial Progress: The company is having positive interactions with the FDA to finalize the design of the Phase 2b study for FSCD, which is expected to initiate in the second half of 2026, marking a significant advancement in its efforts to treat fibro-inflammatory diseases.
- Increased R&D Spending: Research and development expenses for 2025 totaled €48.9 million, up 24.5% from €39.3 million in 2024, primarily due to rising clinical trial costs, reflecting the company's commitment to accelerating product development in key programs.
- Improved Financial Performance: Although the net loss for 2025 was €62.5 million, an increase from €46.3 million in 2024, this indicates ongoing investments in business expansion and clinical trials, with future revenue growth anticipated from new drug launches.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
Universe Pharma Acquires Patent Portfolio, Shares Surge
- Strategic Acquisition: Universe Pharmaceuticals Inc. (UPC) announced a $10.75 million acquisition of 100% of Best Praise International Limited, securing five Chinese patents covering elderly healthcare and cognitive health, with the deal expected to close in Q3 2026, significantly enhancing its competitive edge in the pharmaceutical market.
- Stock Surge: Following the acquisition announcement, UPC's shares soared over 300% to close at $12.18 on Monday, reflecting strong market confidence in its future growth potential and solidifying its position in the Chinese pharmaceutical industry.
- PIPE Financing: Decoy Therapeutics Inc. (DCOY) announced a PIPE financing of up to $21 million, leading to a 70% stock price increase, which includes $3.5 million in upfront proceeds, indicating strong market recognition of its funding capabilities and expected support for future R&D.
- Exploring Business Sale: QuidelOrtho Corp. (QDEL) shares rose over 30% as it explores the sale of its point-of-care testing business for approximately $1.5 billion, attracting interest from several private equity firms, which could provide significant capital inflow to support its strategic transformation.
See More
AgomAb Initiates Phase 2b Trial for Crohn's Disease Drug Ontunisertib
- Trial Design Announcement: AgomAb Therapeutics has unveiled the Phase 2b NOV-ERA trial design for Ontunisertib, an oral small molecule targeting Fibrostenosing Crohn's Disease, aligning with FDA guidelines, indicating the company's strategic positioning in the treatment landscape.
- Patient Recruitment Plan: The company plans to enroll up to 320 patients globally, with participants required to meet specific endoscopic assessment criteria, demonstrating AgomAb's commitment to rigorous clinical trials and addressing unmet patient needs in a market lacking approved therapies.
- Trial Timeline: The trial will consist of a 6-week screening period, a 52-week treatment phase, and a 2-week follow-up, with the primary efficacy endpoint set for Week 24 regarding endoscopic passability, reflecting the company's focus on clinical outcomes and potential market competitiveness.
- Market Outlook Analysis: The global Crohn's disease therapeutics market is projected to reach $13.20 billion in 2023, growing at a CAGR of 2.7% from 2024 to 2030, positioning AgomAb's drug development efforts to capitalize on this rapidly expanding market.
See More
AgomAb Therapeutics Reports Increased Losses for 2025
- Increased Annual Loss: AgomAb Therapeutics NV reported a net loss of €62.5 million for the full year 2025, up from €46.3 million in 2024, indicating significant financial strain and challenges in profitability management.
- Loss Per Share: The basic and diluted loss per share was €143.22, highlighting ongoing operational challenges that could impact investor confidence and future fundraising efforts.
- R&D Spending Growth: Research and development expenses rose to €48.9 million in 2025 from €39.3 million in 2024, reflecting the company's commitment to drug development despite not achieving profitability in the short term.
- Cash Position: As of December 31, 2025, AgomAb held €116.5 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, may be insufficient to sustain operations amid ongoing losses.
See More
Agomab Reports 2025 Financial Results and Future Milestones
- Expanded Financial Loss: Agomab Therapeutics reported a net loss of €62.55 million for the fiscal year 2025, up from €46.27 million the previous year, indicating increased R&D expenditures that may pressure short-term stock performance.
- Strong Cash Reserves: As of December 31, 2025, the company held €116.5 million in cash and cash investments, with gross proceeds of $208 million from its IPO expected to extend its cash runway into the first half of 2029, ensuring operational stability for the coming years.
- Clinical Trial Advancements: Agomab is set to initiate a Phase 2b study for Fibrostenosing Crohn's Disease and a Phase 2 study for Idiopathic Pulmonary Fibrosis in the second half of 2026, demonstrating the company's commitment to advancing its key investigational candidates.
- Stock Price Fluctuations: Since February 2026, AGMB shares have traded between $9 and $17.45, closing at $10.70, reflecting a cautiously optimistic market sentiment regarding the company's upcoming clinical results.
See More
Agomab's IPO Boosts Cash Runway into 2029
- Successful IPO Financing: Agomab completed its IPO in February 2026, raising approximately $208 million in gross proceeds, which is expected to extend the company's cash reserves into the first half of 2029, ensuring funding for its R&D and operational needs.
- Clinical Trial Progress: The company is having positive interactions with the FDA to finalize the design of the Phase 2b study for FSCD, which is expected to initiate in the second half of 2026, marking a significant advancement in its efforts to treat fibro-inflammatory diseases.
- Increased R&D Spending: Research and development expenses for 2025 totaled €48.9 million, up 24.5% from €39.3 million in 2024, primarily due to rising clinical trial costs, reflecting the company's commitment to accelerating product development in key programs.
- Improved Financial Performance: Although the net loss for 2025 was €62.5 million, an increase from €46.3 million in 2024, this indicates ongoing investments in business expansion and clinical trials, with future revenue growth anticipated from new drug launches.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
